Akorn Inc (AKRX) 47.28 $AKRX
19.8% Return Seen to Date on SmarTrend Akorn Call (AKRX)
Comtex SmarTrend(R) - Fri Feb 13, 9:53AM CST
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on January 8th, 2015 at $39.61. In approximately 1 month, Akorn has returned 19.82% as of today's recent price of $47.46.
AKRX: 47.28 (-0.25)
Lannett Near Buy Point After Earnings Beat
at Investor's Business Daily - Thu Feb 12, 10:50AM CST
With the market outlook improving and leading stocks showing healthier action, generic drugmaker Lannett (LCI) is closing in on a potential buy point. The Philadelphia-based firm, which is in the same Medical-Generic Drugs industry group as top-rated...
LCI: 57.78 (-0.91), AKRX: 47.28 (-0.25), HSP: 87.35 (unch)
No Deceleration Here: 14 Stocks With Accelerating Profits
at Investor's Business Daily - Fri Feb 06, 5:29PM CST
According to the latest figures, the American economy grew 2.6% in the fourth quarter, a slowdown from the 5% pickup seen in Q3. Deceleration is generally negative for investors. Thankfully, they can look to the IBD 50 for examples of companies that...
MNST: 117.74 (-1.77), ODFL: 76.25 (+0.96), BIIB: 391.66 (-0.45), SWKS: 81.85 (-0.57), AKRX: 47.28 (-0.25), FLT: 150.37 (+1.15), TSM: 24.84 (+0.37), ALK: 62.56 (-0.19), AVGO: 110.15 (+0.45), CELG: 115.88 (+0.16)
Stocks On Track For Big Weekly Gains
at Investor's Business Daily - Fri Feb 06, 1:56PM CST
Stocks recovered some and were narrowly mixed late Friday. They were also on track to cap the week with big gains. The S&P 500 and Nasdaq were up a fraction, while the Dow Jones industrial average was flat. All three were poised for weekly gains of...
SWIR: 37.45 (+0.12), LNKD: 269.00 (+1.83), AKRX: 47.28 (-0.25), TWTR: 48.50 (+0.55), BWLD: 187.27 (+0.30)
Three Reasons To Let Akorn Fall Into Your Portfolio
at Investor's Business Daily - Fri Feb 06, 10:11AM CST
With a 99 IBD Composite Rating, a stock price trading at all-time highs and a recent run of robust financial growth, generic drug maker Akorn (AKRX) is already a top stock. It might show even more strength in future quarters, thanks to several trends...
PRGO: 150.90 (+0.22), ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58)
Hot Growth Stocks: What Sectors Lead 2015 Now?
at Investor's Business Daily - Thu Feb 05, 5:32PM CST
Think big themes. The list of YWR stocks is a statement on just that. Which companies are growing rapidly? What are the most dynamic business sectors of the economy? The Your Weekly Review tries to objectively answer those questions. If you're new to...
AKRX: 47.28 (-0.25), UTHR: 151.11 (+3.59), MSCC: 30.87 (+0.06), TSM: 24.84 (+0.37), LUV: 43.30 (-0.20)
Stocks Close Near Session Highs, But Volume Softens
at Investor's Business Daily - Thu Feb 05, 3:18PM CST
Stocks closed with a flourish Thursday, although volume dwindled on both exchanges, according to preliminary data. The Nasdaq and S&P 500 rose 1% and the Dow Jones industrial average gained 1.2% in the stock market today. Generic drugmakers were the...
GPRO: 45.27 (-0.02), PRGO: 150.90 (+0.22), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), ORLY: 205.55 (-1.02), BWLD: 187.27 (+0.30), HSP: 87.35 (unch), LCI: 57.78 (-0.91), V: 269.63 (-1.28), LNKD: 269.00 (+1.83), SNCR: 43.89 (+1.06), EXPE: 89.49 (-0.08), DD: 76.18 (-0.11), TEVA: 56.77 (-0.58), TWTR: 48.50 (+0.55)
Stocks Hang Near Day's Highs; Tableau Stays Strong
at Investor's Business Daily - Thu Feb 05, 2:08PM CST
Stocks continued to hold near their best levels late Thursday amid a barrage of corporate earnings, mixed economic reports and a rebound in oil prices. The Dow Jones industrial average climbed 0.9%, while the broader Nasdaq and S&P 500 rose 0.8%...
GPRO: 45.27 (-0.02), AKRX: 47.28 (-0.25), ORLY: 205.55 (-1.02), BWLD: 187.27 (+0.30), ATVI: 23.11 (+0.17), CME: 93.92 (-1.39), LNKD: 269.00 (+1.83), EXPE: 89.49 (-0.08), FLT: 150.37 (+1.15), TWTR: 48.50 (+0.55), DATA: 99.90 (+1.40)
Akorn Stock Is Breaking Out, In Buy Range
at Investor's Business Daily - Thu Feb 05, 12:44PM CST
Akorn (AKRX) is breaking out on the stock market today, boosted by a bullish initiation report. It could also be getting a lift from optimism for more buyouts in the industry: Pfizer (PFE) announced on Thursday that it's buying injectable-drug maker...
AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), HSP: 87.35 (unch)
Stocks Climb In Soft Trade; O'Reilly, Tableau Post Q4 Wins
at Investor's Business Daily - Thu Feb 05, 9:34AM CST
Stocks took and held solid early gains in soft trade Thursday. The Dow Jones industrial average and the S&P 500 each jumped 0.7%. The Nasdaq climbed 0.5%. The stock market today opened on positive footing, despite little support from economic...
AKRX: 47.28 (-0.25), GMCR: 118.53 (+0.56), ORLY: 205.55 (-1.02), PFE: 34.64 (-0.23), DATA: 99.90 (+1.40), HSP: 87.35 (unch)
Akorn, Actavis Near Buy Points Amid Market Turbulence
at Investor's Business Daily - Tue Feb 03, 4:11PM CST
Two of the three generic drug makers in the Spotlight screen remain near buy points amid the market's recent turbulence. Akorn (AKRX) has been seesawing around a 42.64 early buy point of an irregular pattern. The stock cleared the entry Jan. 16, but...
MNK: 115.01 (+2.51), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25)
Latest Updates in Healthcare: Special Research on Agios, Akebia, Akers, Akorn, and Albany
PR Newswire - Tue Feb 03, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Agios (NASDAQ: AGIO), Akebia (NASDAQ: AKBA), Akers (NASDAQ: AKER), Akorn (NASDAQ: AKRX), and Albany (NASDAQ: AMRI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AKRX: 47.28 (-0.25), AKER: 3.50 (+0.20), AKBA: 9.32 (+0.51), AGIO: 118.55 (+0.11), AMRI: 16.94 (-0.28)
Akorn reports February 26
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 10:32AM CST
AKRX: 47.28 (-0.25)
Akorn Announces Fourth Quarter 2014 Earnings Release and Conference Call Information
GlobeNewswire - Thu Jan 29, 6:00AM CST
Akorn, Inc. (Nasdaq:AKRX), expects to release fourth quarter 2014 earnings before the U.S. equities markets open on Thursday, February 26, 2015. In addition, the company will host a conference call at 10:00 a.m. Eastern Standard Time (EST) the same day to discuss fourth quarter 2015 results and provide initial 2015 revenue and earnings guidance.
AKRX: 47.28 (-0.25)
Akorn Set to Join the S&P MidCap 400; United Insurance Holdings, ANI Pharmaceuticals to Join the S&P SmallCap 600
PR Newswire - Tue Jan 27, 4:46PM CST
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
KND: 19.68 (-0.38), UIHC: 27.40 (-0.34), PL: 69.95 (-0.01), ANIP: 62.69 (-0.43), AKRX: 47.28 (-0.25), MHFI: 102.19 (unch), GTIV: 19.19 (-0.23)
Lannett Early Q2 Earnings Beat Estimates; Stock Jumps
at Investor's Business Daily - Mon Jan 26, 11:20AM CST
Generic drugmaker Lannett Co. (LCI) issued preliminary fiscal Q2 earnings Monday that beat expectations, sending its stock up. Lannett said sales for the quarter were about $115 million, nearly double the year-earlier number and well above analysts'...
LCI: 57.78 (-0.91), AKRX: 47.28 (-0.25), NVS: 102.20 (-0.17)
Will New FDA Approvals Boost Leading Drug Stock Akorn?
at Investor's Business Daily - Thu Jan 22, 11:01AM CST
As IBD noted on Jan. 15, there are three reasons why top-rated pharmaceuticals stock Akorn (AKRX) could have a bullish 2015. First, Akorn -- which specializes in difficult-to-manufacture dosage forms, including injectables, opthalmics, oral liquids...
AKRX: 47.28 (-0.25)
FDA clears Akorn ophthalmic solution
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 6:15AM CST
AKRX: 47.28 (-0.25)
Akorn Receives FDA Approval for Phenylephrine HCl Ophthalmic Solution
GlobeNewswire - Tue Jan 20, 6:08AM CST
Akorn, Inc. (Nasdaq:AKRX), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on the Company's New Drug Application (NDA) for Phenylephrine Hydrochloride Ophthalmic Solution, USP, 2.5% and 10%. Akorn intends to re-launch the product shortly.
AKRX: 47.28 (-0.25)
19.8% Return Seen to Date on SmarTrend Akorn Call (AKRX)
Comtex SmarTrend(R) - Fri Feb 13, 9:53AM CST
SmarTrend identified an Uptrend for Akorn (NASDAQ:AKRX) on January 8th, 2015 at $39.61. In approximately 1 month, Akorn has returned 19.82% as of today's recent price of $47.46.
AKRX: 47.28 (-0.25)
Lannett Near Buy Point After Earnings Beat
at Investor's Business Daily - Thu Feb 12, 10:50AM CST
With the market outlook improving and leading stocks showing healthier action, generic drugmaker Lannett (LCI) is closing in on a potential buy point. The Philadelphia-based firm, which is in the same Medical-Generic Drugs industry group as top-rated...
LCI: 57.78 (-0.91), AKRX: 47.28 (-0.25), HSP: 87.35 (unch)
No Deceleration Here: 14 Stocks With Accelerating Profits
at Investor's Business Daily - Fri Feb 06, 5:29PM CST
According to the latest figures, the American economy grew 2.6% in the fourth quarter, a slowdown from the 5% pickup seen in Q3. Deceleration is generally negative for investors. Thankfully, they can look to the IBD 50 for examples of companies that...
MNST: 117.74 (-1.77), ODFL: 76.25 (+0.96), BIIB: 391.66 (-0.45), SWKS: 81.85 (-0.57), AKRX: 47.28 (-0.25), FLT: 150.37 (+1.15), TSM: 24.84 (+0.37), ALK: 62.56 (-0.19), AVGO: 110.15 (+0.45), CELG: 115.88 (+0.16)
Stocks On Track For Big Weekly Gains
at Investor's Business Daily - Fri Feb 06, 1:56PM CST
Stocks recovered some and were narrowly mixed late Friday. They were also on track to cap the week with big gains. The S&P 500 and Nasdaq were up a fraction, while the Dow Jones industrial average was flat. All three were poised for weekly gains of...
SWIR: 37.45 (+0.12), LNKD: 269.00 (+1.83), AKRX: 47.28 (-0.25), TWTR: 48.50 (+0.55), BWLD: 187.27 (+0.30)
Three Reasons To Let Akorn Fall Into Your Portfolio
at Investor's Business Daily - Fri Feb 06, 10:11AM CST
With a 99 IBD Composite Rating, a stock price trading at all-time highs and a recent run of robust financial growth, generic drug maker Akorn (AKRX) is already a top stock. It might show even more strength in future quarters, thanks to several trends...
PRGO: 150.90 (+0.22), ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25), MYL: 55.85 (+1.34), TEVA: 56.77 (-0.58)
Hot Growth Stocks: What Sectors Lead 2015 Now?
at Investor's Business Daily - Thu Feb 05, 5:32PM CST
Think big themes. The list of YWR stocks is a statement on just that. Which companies are growing rapidly? What are the most dynamic business sectors of the economy? The Your Weekly Review tries to objectively answer those questions. If you're new to...
AKRX: 47.28 (-0.25), UTHR: 151.11 (+3.59), MSCC: 30.87 (+0.06), TSM: 24.84 (+0.37), LUV: 43.30 (-0.20)
Stocks Close Near Session Highs, But Volume Softens
at Investor's Business Daily - Thu Feb 05, 3:18PM CST
Stocks closed with a flourish Thursday, although volume dwindled on both exchanges, according to preliminary data. The Nasdaq and S&P 500 rose 1% and the Dow Jones industrial average gained 1.2% in the stock market today. Generic drugmakers were the...
GPRO: 45.27 (-0.02), PRGO: 150.90 (+0.22), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), ORLY: 205.55 (-1.02), BWLD: 187.27 (+0.30), HSP: 87.35 (unch), LCI: 57.78 (-0.91), V: 269.63 (-1.28), LNKD: 269.00 (+1.83), SNCR: 43.89 (+1.06), EXPE: 89.49 (-0.08), DD: 76.18 (-0.11), TEVA: 56.77 (-0.58), TWTR: 48.50 (+0.55)
Stocks Hang Near Day's Highs; Tableau Stays Strong
at Investor's Business Daily - Thu Feb 05, 2:08PM CST
Stocks continued to hold near their best levels late Thursday amid a barrage of corporate earnings, mixed economic reports and a rebound in oil prices. The Dow Jones industrial average climbed 0.9%, while the broader Nasdaq and S&P 500 rose 0.8%...
GPRO: 45.27 (-0.02), AKRX: 47.28 (-0.25), ORLY: 205.55 (-1.02), BWLD: 187.27 (+0.30), ATVI: 23.11 (+0.17), CME: 93.92 (-1.39), LNKD: 269.00 (+1.83), EXPE: 89.49 (-0.08), FLT: 150.37 (+1.15), TWTR: 48.50 (+0.55), DATA: 99.90 (+1.40)
Akorn Stock Is Breaking Out, In Buy Range
at Investor's Business Daily - Thu Feb 05, 12:44PM CST
Akorn (AKRX) is breaking out on the stock market today, boosted by a bullish initiation report. It could also be getting a lift from optimism for more buyouts in the industry: Pfizer (PFE) announced on Thursday that it's buying injectable-drug maker...
AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), HSP: 87.35 (unch)
Stocks Climb In Soft Trade; O'Reilly, Tableau Post Q4 Wins
at Investor's Business Daily - Thu Feb 05, 9:34AM CST
Stocks took and held solid early gains in soft trade Thursday. The Dow Jones industrial average and the S&P 500 each jumped 0.7%. The Nasdaq climbed 0.5%. The stock market today opened on positive footing, despite little support from economic...
AKRX: 47.28 (-0.25), GMCR: 118.53 (+0.56), ORLY: 205.55 (-1.02), PFE: 34.64 (-0.23), DATA: 99.90 (+1.40), HSP: 87.35 (unch)
Akorn, Actavis Near Buy Points Amid Market Turbulence
at Investor's Business Daily - Tue Feb 03, 4:11PM CST
Two of the three generic drug makers in the Spotlight screen remain near buy points amid the market's recent turbulence. Akorn (AKRX) has been seesawing around a 42.64 early buy point of an irregular pattern. The stock cleared the entry Jan. 16, but...
MNK: 115.01 (+2.51), AGN: 229.49 (+1.87), ACT: 285.37 (+3.71), AKRX: 47.28 (-0.25)
Latest Updates in Healthcare: Special Research on Agios, Akebia, Akers, Akorn, and Albany
PR Newswire - Tue Feb 03, 7:40AM CST
Moments ago, Analysts Review released new research updates concerning several important developing situations including Agios (NASDAQ: AGIO), Akebia (NASDAQ: AKBA), Akers (NASDAQ: AKER), Akorn (NASDAQ: AKRX), and Albany (NASDAQ: AMRI). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
AKRX: 47.28 (-0.25), AKER: 3.50 (+0.20), AKBA: 9.32 (+0.51), AGIO: 118.55 (+0.11), AMRI: 16.94 (-0.28)
Akorn reports February 26
Seeking Alpha - at Seeking Alpha - Thu Jan 29, 10:32AM CST
AKRX: 47.28 (-0.25)
Akorn Announces Fourth Quarter 2014 Earnings Release and Conference Call Information
GlobeNewswire - Thu Jan 29, 6:00AM CST
Akorn, Inc. (Nasdaq:AKRX), expects to release fourth quarter 2014 earnings before the U.S. equities markets open on Thursday, February 26, 2015. In addition, the company will host a conference call at 10:00 a.m. Eastern Standard Time (EST) the same day to discuss fourth quarter 2015 results and provide initial 2015 revenue and earnings guidance.
AKRX: 47.28 (-0.25)
Akorn Set to Join the S&P MidCap 400; United Insurance Holdings, ANI Pharmaceuticals to Join the S&P SmallCap 600
PR Newswire - Tue Jan 27, 4:46PM CST
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
KND: 19.68 (-0.38), UIHC: 27.40 (-0.34), PL: 69.95 (-0.01), ANIP: 62.69 (-0.43), AKRX: 47.28 (-0.25), MHFI: 102.19 (unch), GTIV: 19.19 (-0.23)
Lannett Early Q2 Earnings Beat Estimates; Stock Jumps
at Investor's Business Daily - Mon Jan 26, 11:20AM CST
Generic drugmaker Lannett Co. (LCI) issued preliminary fiscal Q2 earnings Monday that beat expectations, sending its stock up. Lannett said sales for the quarter were about $115 million, nearly double the year-earlier number and well above analysts'...
LCI: 57.78 (-0.91), AKRX: 47.28 (-0.25), NVS: 102.20 (-0.17)
Will New FDA Approvals Boost Leading Drug Stock Akorn?
at Investor's Business Daily - Thu Jan 22, 11:01AM CST
As IBD noted on Jan. 15, there are three reasons why top-rated pharmaceuticals stock Akorn (AKRX) could have a bullish 2015. First, Akorn -- which specializes in difficult-to-manufacture dosage forms, including injectables, opthalmics, oral liquids...
AKRX: 47.28 (-0.25)
FDA clears Akorn ophthalmic solution
Seeking Alpha - at Seeking Alpha - Tue Jan 20, 6:15AM CST
AKRX: 47.28 (-0.25)
Akorn Receives FDA Approval for Phenylephrine HCl Ophthalmic Solution
GlobeNewswire - Tue Jan 20, 6:08AM CST
Akorn, Inc. (Nasdaq:AKRX), today announced that it has received approval from the U.S. Food and Drug Administration (FDA) on the Company's New Drug Application (NDA) for Phenylephrine Hydrochloride Ophthalmic Solution, USP, 2.5% and 10%. Akorn intends to re-launch the product shortly.
AKRX: 47.28 (-0.25)
